Drug Profile
Abexinostat - Xynomic Pharmaceuticals
Alternative Names: CG-781; CRA-024781; PCI-24781; S 78454Latest Information Update: 02 Jan 2019
Price :
$50
*
At a glance
- Originator Celera Genomics Group
- Developer GlaxoSmithKline; Massachusetts General Hospital; Pharmacyclics; Servier; University of California at San Francisco; Xynomic Pharmaceuticals
- Class Amides; Antineoplastics; Benzofurans; Dimethylamines; Hydroxamic acids; Phenyl ethers; Small molecules
- Mechanism of Action Histone deacetylase inhibitors; Rad51 recombinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Renal cell carcinoma
- Phase II Chronic lymphocytic leukaemia; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma
- Phase I/II Sarcoma
- No development reported Breast cancer; Myelodysplastic syndromes; Nasopharyngeal cancer; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
Most Recent Events
- 28 Dec 2018 Xynomic Pharma files an IND application with the NMPA in China to evaluate abexinostat as a fourth-line mono therapy against follicular lymphoma
- 01 Sep 2018 Xynomic Pharmaceuticals initiates the phase II FORERUNNER trial for Follicular lymphoma (Second-line therapy or greater) in USA (PO) (NCT03600441)
- 28 Aug 2018 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Capsule)